| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
|
Circulation
|
2003
|
4.25
|
|
2
|
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
|
J Clin Oncol
|
2007
|
3.35
|
|
3
|
Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.
|
J Clin Oncol
|
2007
|
2.86
|
|
4
|
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
|
Lancet Oncol
|
2010
|
2.74
|
|
5
|
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
|
Cancer Res
|
2009
|
2.51
|
|
6
|
Experimental designs for small randomised clinical trials: an algorithm for choice.
|
Orphanet J Rare Dis
|
2013
|
1.77
|
|
7
|
Compliance-guided therapy : a new insight into the potential role of clinical pharmacologists.
|
Clin Pharmacokinet
|
2006
|
1.50
|
|
8
|
ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
|
Cancer Res
|
2012
|
1.22
|
|
9
|
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
|
Breast Cancer Res
|
2008
|
1.10
|
|
10
|
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.
|
Oncoimmunology
|
2012
|
1.05
|
|
11
|
Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival.
|
Ann Hematol
|
2009
|
1.03
|
|
12
|
l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
|
Br J Haematol
|
2011
|
1.02
|
|
13
|
New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear.
|
J Clin Epidemiol
|
2007
|
0.98
|
|
14
|
Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
|
Anticancer Drugs
|
2010
|
0.96
|
|
15
|
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
|
Lung Cancer
|
2008
|
0.93
|
|
16
|
High incidence of mammary intraepithelial neoplasia development in Men1-disrupted murine mammary glands.
|
J Pathol
|
2013
|
0.92
|
|
17
|
Activation of rapid oestrogen signalling in aggressive human breast cancers.
|
EMBO Mol Med
|
2012
|
0.91
|
|
18
|
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.
|
Diabetes Care
|
2003
|
0.89
|
|
19
|
LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer.
|
Int J Cancer
|
2014
|
0.88
|
|
20
|
Validation of prognostic scores for survival in cancer patients beyond first-line therapy.
|
BMC Cancer
|
2011
|
0.87
|
|
21
|
Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
|
Anticancer Drugs
|
2012
|
0.87
|
|
22
|
Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.
|
Eur J Cancer
|
2012
|
0.86
|
|
23
|
Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
|
Anticancer Drugs
|
2013
|
0.85
|
|
24
|
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
|
Clin Cancer Res
|
2008
|
0.85
|
|
25
|
Impact of (18)F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: A prospective multicenter study.
|
AJR Am J Roentgenol
|
2010
|
0.84
|
|
26
|
Evaluation of two evidence-based knowledge transfer interventions for physicians. A cluster randomized controlled factorial design trial: the CardioDAS Study.
|
Fundam Clin Pharmacol
|
2007
|
0.84
|
|
27
|
Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.83
|
|
28
|
Physiologically based model of acute ischemic stroke.
|
J Cereb Blood Flow Metab
|
2002
|
0.83
|
|
29
|
Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial.
|
Eur Heart J
|
2005
|
0.82
|
|
30
|
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
|
Breast Cancer Res Treat
|
2007
|
0.81
|
|
31
|
Intracranial ependymomas in children: society of pediatric oncology experience with postoperative hyperfractionated local radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.81
|
|
32
|
CD4 lymphopenia to identify end-of-life metastatic cancer patients.
|
Eur J Cancer
|
2012
|
0.80
|
|
33
|
Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach.
|
Contemp Clin Trials
|
2009
|
0.79
|
|
34
|
Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
|
Urology
|
2010
|
0.78
|
|
35
|
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
|
BMC Cancer
|
2014
|
0.78
|
|
36
|
Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution.
|
Anticancer Drugs
|
2010
|
0.78
|
|
37
|
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
|
Hematol Oncol
|
2014
|
0.78
|
|
38
|
Contribution of cell culture, RNA extraction, and reverse transcription to the measurement error in quantitative reverse transcription polymerase chain reaction-based gene expression quantification.
|
Anal Biochem
|
2009
|
0.77
|
|
39
|
Significance of serum troponin I elevation in patients with acute aortic dissection of the ascending aorta.
|
Acta Cardiol
|
2005
|
0.77
|
|
40
|
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
|
BMC Cancer
|
2014
|
0.77
|
|
41
|
A comparative study of patients with and without associated digestive surgery in a two-stage hepatectomy setting.
|
Langenbecks Arch Surg
|
2012
|
0.76
|
|
42
|
Development of a rule based prognostic tool for HER 2 positive breast cancer patients.
|
Conf Proc IEEE Eng Med Biol Soc
|
2007
|
0.75
|
|
43
|
A methodological framework for drug development in rare diseases.
|
Orphanet J Rare Dis
|
2014
|
0.75
|
|
44
|
The location of deep-vein thrombosis as a predictive factor for recurrence and cancer discovery after proximal deep-vein thrombosis.
|
Haematologica
|
2003
|
0.75
|
|
45
|
Bioequivalence evaluation of a fixed combination of chloroquine and proguanil in a capsule formulation versus a standard medication.
|
Arzneimittelforschung
|
2002
|
0.75
|
|
46
|
[New approaches in pharmacology: numerical modelling and simulation].
|
Therapie
|
2005
|
0.75
|
|
47
|
Optimizing drug development in oncology by clinical trial simulation: Why and how?
|
Brief Bioinform
|
2017
|
0.75
|
|
48
|
Active breathing control for Hodgkin's disease in childhood and adolescence: feasibility, advantages, and limits.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.75
|
|
49
|
Time-to-event analysis with artificial neural networks: an integrated analytical and rule-based study for breast cancer.
|
Neural Netw
|
2007
|
0.75
|